Baillie Gifford & Co. Cuts Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Baillie Gifford & Co. trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 5.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 25,239,870 shares of the company’s stock after selling 1,350,066 shares during the period. Baillie Gifford & Co. owned approximately 0.09% of Recursion Pharmaceuticals worth $166,331,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Farther Finance Advisors LLC increased its holdings in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the last quarter. Amalgamated Bank boosted its stake in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC bought a new position in Recursion Pharmaceuticals in the 3rd quarter worth about $69,000. 89.06% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total transaction of $120,800.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at $4,606,442.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total value of $81,502.64. Following the sale, the director now directly owns 7,132,769 shares in the company, valued at $50,785,315.28. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 156,682 shares of company stock worth $1,012,618 over the last quarter. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Shares of NASDAQ RXRX opened at $7.84 on Tuesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 6.07. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.22 and a 1 year high of $15.74. The firm has a fifty day moving average price of $6.58 and a 200-day moving average price of $7.62. The stock has a market cap of $2.20 billion, a PE ratio of -5.12 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.43) earnings per share. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RXRX. Jefferies Financial Group decreased their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Finally, Leerink Partners decreased their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.